Digital Look

Welcome to Digital Look++,
you are not logged in

Indivior (INDV)

Pharma and Biotech

879.50p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
31-Mar-25	Q1	266.00	59.00	38.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	647.00	(173.00)	40.00¢	18.2	n/a	-67%	n/a	0.0%
31-Dec-21	791.00	190.00	19.20¢	89.4	n/a	-52%	n/a	0.0%
31-Dec-22	901.00	(95.00)	(38.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	1,093.00	1.00	1.00¢	1,583.3	n/a	n/a	n/a	0.0%
31-Dec-24	1,188.00	(43.00)	(36.00)¢	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	1,055.30	247.10	97.51p	8.8	n/a	n/a	n/a	0.0%
31-Dec-26	1,088.78	262.74	113.42p	7.6	0.5	+16%	n/a	0.0%
31-Dec-27	1,147.38	295.08	130.09p	6.6	0.4	+15%	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	18.58	n/a	304.78	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.